title: Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.
authors.forename: Niels P
authors.initials: NP
authors.lastname: Riksen
authors.forename: Gerard A
authors.initials: GA
authors.lastname: Rongen
authors.forename: Paul
authors.initials: P
authors.lastname: Smits
authors.forename: Piet
authors.initials: P
authors.lastname: van Riel
authors.forename: Pilar
authors.initials: P
authors.lastname: Barrera
mesh_terms: D000659:AMP Deaminase / Q000235:genetics* / Q000378:metabolism; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D004351:Drug Resistance / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D018482:Muscle, Skeletal / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D000659:AMP Deaminase; C514117:AMPD1 protein, human; D008727:Methotrexate